Selexipag
- Generic Name
- Selexipag
- Brand Names
- Uptravi, Uptravi Titration Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C26H32N4O4S
- CAS Number
- 475086-01-2
- Unique Ingredient Identifier
- 5EXC0E384L
- Background
Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. Marketed by Actelion Pharmaceuticals und...
- Indication
Selexipag is indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.
- Associated Conditions
- Pulmonary arterial hypertension WHO functional class I
- Associated Therapies
- -
Pulmonary Hypertension: Intensification and Personalisation of Combination Rx
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-12-03
- Target Recruit Count
- 40
- Registration Number
- NCT05825417
- Locations
- 🇬🇧
Sheffield Teaching Hospitals NHS FT, Sheffield, United Kingdom
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
- Conditions
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Actelion
- Target Recruit Count
- 230
- Registration Number
- NCT05179876
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, China
🇧🇾The Republican Scientific-Practical Center ''Cardiology'', Minsk, Belarus
🇧🇾Minsk Regional Clinical Hospital Of The Red Banner Of Labor, Minsk, Belarus
Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Actelion
- Registration Number
- NCT04914247
Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04589390
- Locations
- 🇧🇷
Universidade de São Paulo, São Paulo, SP, Brazil
A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Actelion
- Target Recruit Count
- 43
- Registration Number
- NCT04565990
- Locations
- 🇰🇷
The Catholic University of Korea Seoul St Marys Hospital, Seoul, Korea, Republic of
🇧🇾The Republican Scientific-Practical Center ''Cardiology'', Minsk, Belarus
🇧🇾Minsk Regional Clinical Hospital, Minsk, Belarus
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
- Conditions
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Actelion
- Target Recruit Count
- 138
- Registration Number
- NCT04175600
- Locations
- 🇵🇹
Uls Sao Joao - Hosp. Sao Joao, Porto, Portugal
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇵🇹Uls Sao Jose - Hosp. Santa Marta, Lisboa, Portugal
A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag
- Conditions
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Actelion
- Target Recruit Count
- 10
- Registration Number
- NCT03942211
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸St. Vincent Medical Group, Inc., Indianapolis, Indiana, United States
A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment
- Conditions
- Interventions
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Actelion
- Target Recruit Count
- 128
- Registration Number
- NCT03689244
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇨🇦Institut Universitaire De Cardiologie Et De Pneumologie De Québec, Quebec, Canada
A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- Actelion
- Target Recruit Count
- 22
- Registration Number
- NCT03496506
- Locations
- 🇧🇪
Clinical Pharmacology Unit (CPU), Merksem, Belgium
Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
- First Posted Date
- 2017-03-14
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Actelion
- Target Recruit Count
- 108
- Registration Number
- NCT03078907
- Locations
- 🇺🇸
LA Biomedical Research Institute, Torrance, California, United States
🇺🇸Tufts Medical Center, Pulmonary/Critical Care & Sleep, Boston, Massachusetts, United States
🇺🇸University of Cincinnati, Heart, Lung and Vascular Institute, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.